Skip to main content

Table 5 Cytokine production of naive CD4+ T-cells from healthy donors (HD) and patients (Pat) with/without MSCs

From: Mesenchymal stem cells modulate IL-17 and IL-9 production induced by Th17-inducing cytokine conditions in autoimmune arthritis: an explorative analysis

 

HD

Pat

MSCs

No MSCs

MSCs

No MSCs

Cytokine production

% CD4+ T-cells

Absolute count

IFNγ-production

TEMRA in %

Absolute count

0.0 ± 0.1 (0.0; 0.0–0.1)

0 ± 30

(0; 0–30)

0.1 ± 0.2 (0.1; 0.0–0.3)

30 ± 60

(30; 0–90)

0.2 ± 0.2 (0.2; 0.0–0.5)

60 ± 60

(60; 0–150)

0.3 ± 0.5; (0.0; 0.0–1.0)

90 ± 150

(0; 0–300)

Naive in %

Absolute count

0.0 ± 0.1 (0.0; 0.0–0.1)

0 ± 30

(0; 0–30)

0.3 ± 0.1 (0.3; 0.1–0.4)a

90 ± 30

(90; 30–120)

0.3 ± 0.4 (0.3; 0.0–0.8)

90 ± 120

(90; 0–240)

0.6 ± 0.9 (0.2; 0.0–1.9)

180 ± 270

(60; 0–570)

Memory in %

Absolute count

1.1 ± 0.9 (1.3; 0.0–1.9)

330 ± 270

(390; 0–570)

4.5 ± 1.6 (4.0; 3.3–6.8)b

1350 ± 480

(1200; 990–2040)

1.6 ± 2.1 (1.1; 0.0–4.4)

480 ± 630

(330; 0–1320)

3.3 ± 1.8 (3.0; 1.4–5.8)

990 ± 540

(900; 420–1740)

Effector in %

Absolute count

0.3 ± 0.5 (0.1; 0.0–0.1)

90 ± 150

(30; 0–30)

2.6 ± 2.1 (2.3; 0.6–5.4)

780 ± 630

(690; 180–1620)

0.1 ± 0.2 (0.1; 0.0–0.3)

30 ± 60

(30; 0–90)

2.2 ± 2.2 (1.7; 0.1–5.3)

660 ± 660

(510; 30–1590)

IL-17-production

TEMRA in %

Absolute count

0.0 ± 0.0 (0.0; 0.0–0.0)

0 ± 0

(0; 0–0)

0.0 ± 0.0 (0.0; 0.0–0.0)

0 ± 0

(0; 0–0)

0.0 ± 0.0 (0.0; 0.0–0.0)

0 ± 0

(0; 0–0)

0.0 ± 0.0 (0.0; 0.0–0.0)

0 ± 0

(0; 0–0)

Naive in %

Absolute count

0.1 ± 0.1 (0.1; 0.0–0.3)

30 ± 30

(30; 0–90)

0.1 ± 0.1 (0.1; 0.0–0.3)

30 ± 30

(30; 0–90)

0.3 ± 0.4 (0.2; 0.0–0.8)

90 ± 120

(60; 0–240)

0.2 ± 0.2 (0.3; 0.0–0.3)

60 ± 60

(90; 0–90)

Memory in %

Absolute count

0.4 ± 0.2 (0.4; 0.3–0.7)

120 ± 60

(120; 90–210)

0.3 ± 0.2 (0.4; 0.1–0.7)

90 ± 60

(120; 30–210)

0.4 ± 0.2 (0.5; 0.1–0.5)

120 ± 60

(150; 30–150)

0.8 ± 0.8 (0.6; 0.1–1.9)

240 ± 240

(180; 30–570)

Effector in %

Absolute count

0.2 ± 0.1 (0.2; 0.0–0.3)

60 ± 30

(60; 0–90)

0.5 ± 0.2 (0.5; 0.2–0.7)

150 ± 60

(150; 60–210)

0.1 ± 0.1 (0.2; 0.0–0.2)

30 ± 30

(60; 0–60)

0.6 ± 0.2 (0.7; 0.4–0.8)c

180 ± 60

(210; 120–240)

IL-9-production

TEMRA in %

Absolute count

0.1 ± 0.1 (0.1; 0.0–0.1)

30 ± 30

(30; 0–30)

0.2 ± 0.2 (0.2; 0.0–0.4)

60 ± 60

(60; 0–120)

0.3 ± 0.4 (0.1; 0.0–0.9)

90 ± 120

(30; 0–270)

0.5 ± 0.7 (0.2; 0.0–1.5)

150 ± 210

(60; 0–450)

Naive in %

Absolute count

0.2 ± 0.2 (0.2; 0.1–0.5)

60 ± 60

(60; 30–150)

0.2 ± 0.1 (0.2; 0.1–0.3)

60 ± 30

(60; 30–90)

0.9 ± 1.4 (0.3; 0.1–3.0)

270 ± 420

(90; 30–900)

0.8 ± 0.9 (0.5; 0.1–2.0)

240 ± 270

(150; 30–600)

Memory in %

Absolute count

0.5 ± 0.5 (0.3; 0.2–1.2)

150 ± 150

(90; 60–360)

1.6 ± 1.4 (1.1; 0.5–3.6)

480 ± 420

(330; 150–1080)

0.7 ± 0.6 (0.5; 0.3–1.6)

210 ± 180

(150; 90–480)

1.9 ± 1.3 (1.8; 0.5–3.6)

570 ± 390

(480; 150–1080)

Effector in %

Absolute count

0.2 ± 0.1 (0.2; 0.0–0.3)

60 ± 30

(60; 0–90)

3.5 ± 3.7 (2.6; 0.1–8.8)

1050 ± 1110

(780; 30–2640)

0.1 ± 0.1 (0.1; 0.0–0.1)

30 ± 30

(30; 0–30)

2.7 ± 3.4 (1.6; 0.2–7.6)d

810 ± 1020

(2640; 60–2280)

  1. Average percentage of cytokine producing positive cells and absolute count within the CD4+ T cell subpopulations of TEMRA, Naive, Memory and Effector cells based on naive CD4+ T-cells after Th17 stimulation over 6 days. HD = healthy donors. Pat = patients. Values are shown as follows: mean ± standard deviation (median; minimum–maximum)
  2. aDifferences between IFNγ-production of the naive phenotype in HD with MSCs vs. without MSCs: p = 0.029 (Mann–Whitney-U-Test)
  3. bDifferences between IFNγ-production of the memory phenotype in HD with MSCs vs. without MSCs: p = 0.029 (Mann–Whitney-U-Test)
  4. cDifferences between IL-17-production of the effector phenotype in Pat with MSCs vs. without MSCs: p = 0.029 (Mann–Whitney-U-Test)
  5. dDifferences between IL-9-production of the effector phenotype in Pat with MSCs vs. without MSCs: p = 0.029 (Mann–Whitney-U-Test)
  6. There were no significant differences between the cytokine production of other phenotypes in Pat or HD with MSCs vs. without MSCs (Mann–Whitney-U-Test)
Back to article page

Advances in Rheumatology

ISSN: 2523-3106